OrthoPediatrics rose 4% after hours after the FDA, the U.S. agency that regulates medical devices, cleared its pediatric thighbone nail system.
Why OrthoPediatrics Stock Is Up After Hours
OrthoPediatrics Corp. is up 4% after hours at $25.00 after the FDA cleared its new nail system for children’s thighbones. The company also reported completing the first procedures using it. Shares stayed near the session high after the close, showing buyers held the gain rather than quickly selling.
What OrthoPediatrics Corp. Does
OrthoPediatrics focuses on orthopedic care for children and sells implants and tools for injuries, bone deformities, and spine conditions. Its products are built around children’s needs, which can differ from those addressed by adult-focused systems. This new system adds another option to its existing product line.
OrthoPediatrics Pediatric Nail System Clearance
The clearance allows the device to be marketed in the United States. The system includes nails for treating thighbone injuries and straight nails for correcting bone deformities. A retrograde nail is a metal rod inserted into a bone from the end near the knee to stabilize or correct it.
OrthoPediatrics Nail System Release
The company plans a limited market release for the remainder of 2026, with broader commercialization planned for 2027. That staged launch means the commercial benefit will depend on whether more surgeons and hospitals begin using it.
OrthoPediatrics Third Quarter Revenue Growth
OrthoPediatrics also reported third-quarter revenue of $72.7 million, up 19% from a year earlier. That growth shows demand was already rising across the business before this launch.
Quick Financial Overview
OrthoPediatrics has real product sales but reported a net loss in its June quarter. It is a small-cap, a smaller listed company worth $652.8M across all its shares. It held $45.9M in cash, cash equivalents, and short-term investments as of June 30, 2026, including money readily available or easily turned into cash.
OrthoPediatrics June Revenue and Earnings
In that quarter, revenue was $70.5M and the company had a net loss of $7.2M. Sales show the business is bringing in money, but the loss means those sales did not produce an overall profit.
OrthoPediatrics Public Float
The float, or shares available for public trading, is about 16 million shares. This describes the supply investors can trade, rather than the company’s total share count.
OrthoPediatrics Stock Near Its Monthly High
OrthoPediatrics is trading near its monthly high after a longer climb. Shares are up 57% over six months, showing the advance began well before this product news. For perspective, the last daily move this large was five sessions ago.
Conclusion
The broader launch is the next business test, with no specific launch date announced. If surgeons and hospitals adopt the system, it could add to product sales; if use stays limited, the financial benefit will remain unproven.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.